These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11604470)

  • 21. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
    Nakamura JL; Karlsson A; Arvold ND; Gottschalk AR; Pieper RO; Stokoe D; Haas-Kogan DA
    J Neurooncol; 2005 Feb; 71(3):215-22. PubMed ID: 15735908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of PTEN and Akt in the regulation of growth and apoptosis in human osteoblastic cells.
    Nielsen-Preiss SM; Silva SR; Gillette JM
    J Cell Biochem; 2003 Dec; 90(5):964-75. PubMed ID: 14624456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells.
    Li DM; Sun H
    Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15406-11. PubMed ID: 9860981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disruption of a single Pten allele augments the chemotactic response of B lymphocytes to stromal cell-derived factor-1.
    Fox JA; Ung K; Tanlimco SG; Jirik FR
    J Immunol; 2002 Jul; 169(1):49-54. PubMed ID: 12077227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mammalian target of rapamycin.
    Meric-Bernstam F; Mills GB
    Semin Oncol; 2004 Dec; 31(6 Suppl 16):10-7; discussion 33. PubMed ID: 15799239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
    Wacheck V
    Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
    Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
    Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes.
    Cheney IW; Neuteboom ST; Vaillancourt MT; Ramachandra M; Bookstein R
    Cancer Res; 1999 May; 59(10):2318-23. PubMed ID: 10344736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN.
    Mourani PM; Garl PJ; Wenzlau JM; Carpenter TC; Stenmark KR; Weiser-Evans MC
    Circulation; 2004 Mar; 109(10):1299-306. PubMed ID: 14993145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
    Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
    Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic lethality: killing cancer with cancer.
    Garber K
    J Natl Cancer Inst; 2002 Nov; 94(22):1666-8. PubMed ID: 12441317
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PTEN expression causes feedback upregulation of insulin receptor substrate 2.
    Simpson L; Li J; Liaw D; Hennessy I; Oliner J; Christians F; Parsons R
    Mol Cell Biol; 2001 Jun; 21(12):3947-58. PubMed ID: 11359902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells.
    Tanaka M; Koul D; Davies MA; Liebert M; Steck PA; Grossman HB
    Oncogene; 2000 Nov; 19(47):5406-12. PubMed ID: 11103942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.
    Podsypanina K; Lee RT; Politis C; Hennessy I; Crane A; Puc J; Neshat M; Wang H; Yang L; Gibbons J; Frost P; Dreisbach V; Blenis J; Gaciong Z; Fisher P; Sawyers C; Hedrick-Ellenson L; Parsons R
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10320-5. PubMed ID: 11504907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.
    Mills GB; Lu Y; Kohn EC
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10031-3. PubMed ID: 11526226
    [No Abstract]   [Full Text] [Related]  

  • 38. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
    Ozes ON; Akca H; Mayo LD; Gustin JA; Maehama T; Dixon JE; Donner DB
    Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4640-5. PubMed ID: 11287630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incorporating molecular tools into early-stage clinical trials.
    Weil RJ
    PLoS Med; 2008 Jan; 5(1):e21. PubMed ID: 18215108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.